Implantation of Engineered Cartilage Grafts for Treatment of Patellofemoral Osteoarthritis Versus Surgical Comparators.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-15

Study Completion Date

2030-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

ENCANTO is a randomized, controlled, multi-center phase II clinical trial for the treatment of patellofemoral osteoarthritis (PFOA) with an Advanced Therapy Medicinal Product (ATMP), nasal chondrocyte-based tissue engineered cartilage (N-TEC) implantation in comparison with current standard of care depending on the stage of osteoarthritis. The goal of this phase II trial is to evaluate the efficacy of N-TEC treatment in comparison to an active comparator Autologous Matrix Induced Chondrogenesis (AMIC) for early stage PFOA or patellofemoral arthroplasty (PFA) for late stage PFOA.

The N-TEC engineered cartilage graft is obtained by culturing expanded autologous nasal chondrocytes within a collagen type I/III membrane.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Patellofemoral Osteoarthritis With Engineered Cartilage.

NCT06163573

Patellofemoral Osteoarthritis

RECRUITING PHASE2

Clinical Trial for the Regeneration of Cartilage Lesions in the Knee

NCT02673905

Tear; Knee, Cartilage, Articular

COMPLETED NA

Tissue Engineered Nasal Cartilage for Regeneration of Articular Cartilage

NCT01605201

Cartilage Lesion Degenerative Lesion of Articular Cartilage of Knee

COMPLETED PHASE1

3DKnee™ System vs. the MJS Knee System

NCT00764803

Rheumatoid Arthritis Traumatic Arthritis Joint Disease Secondary to Osteoarthritis

TERMINATED

Confirmatory Study of NeoCart in Knee Cartilage Repair

NCT01066702

Articular Cartilage Defects in the Knee Joint

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Knee osteoarthritis (OA) is one of the most common causes for pain and disability with over 260 million people affected worldwide. Recent studies found that knee OA often starts in the patello-femoral compartment of the knee (PFOA) and is diagnosed in \~39% of people with knee pain aged above 30 years. Thus, PFOA and progression to full OA plays a crucial role in the reduction of quality of life of many people and in the raise of healthcare costs.

The goal of this multi-center phase II trial is to (i) evaluate the efficacy of N-TEC treatment in comparison to an active comparator Autologous Matrix Induced Chondrogenesis (AMIC) for early stage PFOA or patellofemoral arthroplasty (PFA) for late stage PFOA based on patient self-assessed questionnaires (Knee Injury and Osteoarthritis Outcome Score, KOOS) and (ii) verify the postulated mode of action, which is expected to be of regenerative nature and will be assessed by evaluation of disease-modification by x- ray and structural regeneration of the osteoarthritic joint destruction by MRI analysis. A total of 150 patients with early stage of PFOA (Iwano grade 1-2; 75 patients) or late stage of PFOA (Iwano grade 3-4; 75 patients) will be enrolled in 11 clinical centers and randomized to either N-TEC implantation or active comparator (AMIC or PFA).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patellofemoral Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Engineered cartilage graft (N-TEC)-Iwano grade 1-2

N-TEC is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membranes for 2 weeks to allow cells to produce extracellular matrix containing cartilage specific proteins. The IMP is implanted in the knee at the patellofemoral joint.

Group Type EXPERIMENTAL

Engineered cartilage graft (N-TEC)

Intervention Type BIOLOGICAL

Nasal chondrocytes based tissue engineered cartilage

Autologous Matrix Induced Chondrogenesis-Iwano grade 1-2

AMIC® Chondro-Gide® combines microfracturing (MFx) with the use of Chondro-Gide®, which covers and protects both the super clot resulting from MFx and the repair tissue.

Group Type ACTIVE_COMPARATOR

Autologous Matrix Induced Chondrogenesis (AMIC)

Intervention Type PROCEDURE

Autologous Matrix Induced Chondrogenesis is performed through bone drilling and covering with Chondro-Gide® to attract bone marrow stem cells

Engineered cartilage graft (N-TEC)-Iwano grade 3-4

N-TEC is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membranes for 2 weeks to allow cells to produce extracellular matrix containing cartilage specific proteins. The IMP is implanted in the knee at the patellofemoral joint.

Group Type EXPERIMENTAL

Engineered cartilage graft (N-TEC)

Intervention Type BIOLOGICAL

Nasal chondrocytes based tissue engineered cartilage

Patellofemoral Arthroplasty (PFA)-Iwano grade 3-4

Patellofemoral Joint Prosthesis

Group Type ACTIVE_COMPARATOR

Patellofemoral Arthroplasty (PFA)

Intervention Type PROCEDURE

Surgical implantation of a medical device, Zimmer Gender Solutions Patellofemoral Joint Prosthesis.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Engineered cartilage graft (N-TEC)

Nasal chondrocytes based tissue engineered cartilage

Intervention Type BIOLOGICAL

Autologous Matrix Induced Chondrogenesis (AMIC)

Autologous Matrix Induced Chondrogenesis is performed through bone drilling and covering with Chondro-Gide® to attract bone marrow stem cells

Intervention Type PROCEDURE

Patellofemoral Arthroplasty (PFA)

Surgical implantation of a medical device, Zimmer Gender Solutions Patellofemoral Joint Prosthesis.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient age is ≥18 and ≤ 70 years at time of screening.
* Symptomatic PFOA grade 1-4 according to Iwano Classification
* Chondropathy Grade 3-4 according to ICRS classification of the patella, trochlea femoris or both
* Baseline score of \<75 on the KOOS-5 subjective knee evaluation.
* Free range of motion of the affected knee joint or ≤ 5° of extension loss and minimum 125° flexion.
* Patient is willing and able to give written informed consent to participate in the study and to comply with all study requirements, including attending all follow-up visits and assessments and to complete postoperative rehabilitation regimen.
* Minimum values for women: Haemoglobin 120g/l, Platelets 150G/l, INR\<1.3
* Minimum values for men: Haemoglobin 140g/l, Platelets 150G/l, INR\<1.3
* Patients have failed to demonstrate adequate response to non-pharmacological interventions (e.g. structured land-based exercise programs) and pharmacological first-line treatment such as topical NSAIDs

Exclusion Criteria

* Patient is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol or in a dependency or employment with the sponsor.
* Patient is unwilling, unable or lacking the capacity to provide informed consent
* Patient is unable to undergo magnetic resonance imaging (MRI)
* Prior surgical treatment of the target knee within 12 months (Note: prior diagnostic arthroscopy with debridement and lavage are acceptable within 12 months).
* Radiologically apparent degenerative joint disease of the tibiofemoral joint as determined by X-ray (Kellgren and Lawrence grade \> 2) or MRI or pain in the tibiofemoral joint as assessed by clinical examination
* Patient has excessive varus or valgus deformity (\>5°), unless corrected during implantation
* Patient has a symptomatic meniscus lesion (or removal exceeding ½), as indicated by clinical examination (joint line tenderness and McMurray test positive) and MRI.
* Patient has a body mass index (BMI) \>35 kg/m2.
* Patient has chronic rheumatoid arthritis, and/or infectious arthritis
* Any concomitant painful or disabling disease of the spine, hips, or lower limbs that would interfere with evaluation of the afflicted knee.
* Patient has a known immunological suppressive disorder or is taking systemic immunosuppressives.
* Patient had any intra-articular injections into the affected knee within the last 3 months before baseline visit
* Instability of anterior, posterior and/or collateral ligaments
* The patient has a HIV/AIDS infection. (regulatory requirement)
* The patient has an acute Treponema pallidum (syphilis) infection. (regulatory requirement)
* The patient has an active hepatitis B or C infection with verified antigens. Patients with a cured hepatitis B or C infection and/or verified antibodies are not excluded. (regulatory requirement)
* Patient is pregnant, breast feeding or anticipates becoming pregnant within 24 months after surgery.
* Patient is currently participating or has participated in any other clinical study within 3 months prior to the screening visit.
* Patient has known current or recent history of illicit drug or alcohol abuse or dependence defined as the continued use of alcohol or drugs despite the development of social, legal or health problems.
* Patient has any other condition, which, in the opinion of the investigator, would make the patient unsuitable for the study.
* Known allergies for porcine collagen (scaffold), penicillin or streptomycin (manufacturing)
* Nail-patella syndrome
* Patients who will likely benefit from conservative therapy, such as physiotherapy, medical training therapy and pain medication
* Patients with increased anesthesiological and surgical risks (e.g. known or predicted difficult airway, myocardial infarction \<60 days prior to surgery)
* Patients with increased bleeding risk (e.g. coagulopathies)
* Patients on anticoagulants whose anticoagulant therapy cannot be interrupted as appropriate to the given agent(s) and underlying condition
* Patients with any active infections

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Orthopedic Hospital Vienna-Speising

Vienna, , Austria

Site Status RECRUITING